Sarah Cannon Research Institute
Kathryn Mealey has a diverse work experience history. Kathryn began their career in 2011, working as a Graduate Research Assistant at Saint Louis University. In 2011, they also took on an Intern/Associate role at Kantar Health. From 2013 to 2018, they worked at Vanderbilt University Medical Center, starting as a Clinical Research Coordinator II and progressing to become a Research Programs Manager. In 2018, Kathryn joined the Sarah Cannon Research Institute, serving as the Director of Regulatory Affairs until 2021 and then transitioning to their current role as the Director of NCI Clinical Research Program.
Kathryn Mealey graduated from Vanderbilt University in 2009 with a Bachelor of Arts (B.A.) degree in Neuroscience. Kathryn then pursued further education at Saint Louis University from 2010 to 2012, earning a Master of Public Health (MPH) degree in Epidemiology. Prior to their college education, Kathryn attended Mary Institute and St. Louis Country Day School (MICDS) from 2002 to 2006.
This person is not in any teams
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.